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OBJECTIVE: Early identification of HIV infection is
critical for patients to receive life-prolonging treatment
and risk-reduction counseling. Understanding HIV
screening practices and barriers to HIV testing is an
important prelude to designing successful HIV screen-
ing programs. Our objective was to evaluate current
practice patterns for identification of HIV.
METHODS: We used a retrospective cohort analysis of
13,991 at-risk patients seen at 4 large Department of
Veterans Affairs (VA) health-care systems. We also
reviewed 1,100 medical records of tested patients. We
assessed HIV testing rates among at-risk patients, the
rationale for HIV testing, and predictors of HIV testing
and of HIV infection.
RESULTS: Of the 13,991 patients at risk for HIV, only
36% had been HIV-tested. The prevalence of HIV ranged
from 1% to 20% among tested patients at the 4 sites.
Approximately 90% of patients who were tested had a
documented reason for testing.
CONCLUSION: One-half to two-thirds of patients at risk
for HIV had not been tested within our selected VA sites.
Among tested patients, the rationale for HIV testing was
well documented. Further testing of at-risk patients
could clearly benefit patients who have unidentified HIV
infection by providing earlier access to life-prolonging
therapy.
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INTRODUCTION
Early identification of HIV disease is essential for both clinical
care and prevention of HIV transmission. Antiretroviral
therapy has dramatically improved survival with HIV-1
disease,
1,2 and the initiation of therapy early provides a
substantial increase in life expectancy compared to therapy
begun late in the course of disease.
3 Early identification also
contributes to reduced HIV transmission
3 because appropri-
ately devised counseling reduces risk behaviors,
4–6 people
who become aware they have HIV change their behavior,
7 and
antiretroviral therapy reduces viral load, which provides an
additional reduction in transmission.
3 Finally, screening for
HIV is cost effective,
3,8,9 even when the prevalence of HIV is as
low as 0.05%, which would include the vast majority of health-
care settings.
Despite the clear individual and public health advantages of
early identification of HIV infection, data from the Centers for
Disease Control and Prevention (CDC) indicate that between
42% and 59% of the approximately 850,000 to 950,000 people
with HIV/AIDS infection have either not been identified or are
not receiving treatment.
10 The CDC also estimates that as
many as 20,000 new HIV infections are attributable to
transmission from individuals who did not know they were
infected with HIV.
11 Surveillance data from the CDC indicate
that 43% of HIV-positive patients first learned they had HIV
within a year of developing AIDS,
12 and other studies have
found that approximately 40% of patients have a CD4
lymphocyte count of less than 200 cells/μL at the time of
diagnosis, an indication of advanced disease.
13,14 Thus, many
people are diagnosed late in the disease process, which
indicates that current approaches to early identification are
inadequate. This evidence led the CDC to recommend recently
that all adolescents and adults in the United States between
the ages of 13 and 64 years of age be tested for HIV.
15
To help understand how to improve early identification of
HIV infection, we undertook a study to evaluate the existing
practice patterns for the identification of HIV infection at
selected sites within the Department of Veterans Affairs (VA).
The VA is one of the largest health-care systems in the United
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315States, and quality of care in the VA compares favorably with
private-sector delivery systems.
16–18 The VA is also the largest
provider of HIV health care in the United States and one of the
largest providers of HIV care in the world, with over 19,000
HIV-infected patients in care.
19 Because of the large number of
patients served, testing in large health-care delivery systems is
of special importance.
13 We evaluated whether patients at risk
for HIV were being tested, the rationale for testing in those who
were tested, predictors of testing, and predictors of HIV
infection in 4 large VA health care centers.
METHODS
We used 2 approaches to assess existing practice patterns for
HIV screening and testing in the VA: (1) an analysis of a cohort
of at-risk patients and (2) an analysis of a cohort of tested
patients for a 1-year period. Our analysis of tested patients
used both a computer-based analysis of a cohort of all HIV-
tested patients for a 1-year period and a detailed medical
record review of a subset of these patients.
W ec h o s e4l a r g eV AH e a l t hC a r eS y s t e m st h a tw e r e
geographically dispersed (3 on the west coast and 1 on the
east coast) and that had estimated HIV prevalence that varied
from 0.5% to 2.1%, based on the VA Immunology Case
Registry.
20 These centers cared for between approximately
180 and 1,000 patients with HIV each. The research was
approved by the institutional review board at each site. We
took extensive precautions to protect patient confidentiality.
The funders had no role in the design, conduct, interpretation,
or reporting of this study.
Analysis of At-Risk Cohort
We used the VA Medical Inpatient and Outpatient Data Sets of
the National Patient Care Database to select a cohort of VA
patients who were seen between October 1, 1998, and Septem-
ber 30, 1999, at 4 VA medical centers and were at risk for HIV
infection. We defined patients to be at risk for HIV infection if
their record contained ICD-9 codes
21 for substance use (specif-
ically, alcohol use, amphetamine use, barbiturate use, canna-
bis use, cocaine use, opioid use, hallucinogen use, other drug
use, and unspecified and drug psychosis), hepatitis B, hepatitis
C, all viral hepatitis (other than hepatitis B or C), or sexually
transmitted disease at any visit during this time period.
Because there is controversy about which ICD-9 codes put
patients at increased risk, in sensitivity analyses, we used
successively more restrictive definitions of risk factors, with the
most restrictive definition including only cocaine, opiate, or am-
phetamine use. We also collected data on demographic charac-
teristics and selected comorbid conditions (e.g., pneumonia/
influenza, septicemia, chronic liver disease) for the cohort.
We determined whether these patients had been tested for
HIV within the VA during the 5-year period from October 1,
1995, to September 30, 2000, by using the Veterans Health
Information Systems and Technology Architecture (VISTA). We
included the 3 years prior to October 1, 1998, because if a
patient had been tested during this time, a repeat HIV test may
not have been necessary. A test result was considered positive
or indeterminate on the basis of the Western blot test result. It
was not feasible for us to determine whether patients at risk
had been tested outside the VA.
Analysis of Tested Cohort
We obtained HIV testing information from VISTA for the cohort
of patients who received an HIV test from October 1, 1998, to
September 30, 1999, at the 4 VA medical centers. We matched
this cohort to data from the VA Medical Inpatient and
Outpatient Data Sets, for the period between October 1,
1995, and September 30, 1999, to obtain data on demograph-
ics, comorbid conditions, and risk factors based on ICD-9
diagnoses codes.
21 We excluded patients who were nonveter-
ans and for whom gender information was inconsistent.
We chose a random subsample of the cohort of HIV-tested
patients for a detailed medical record review. We conducted
275 medical record reviews each at the 4 health care centers.
The medical record review assessed if the patient had a
documented risk factor for HIV, the indications for testing,
and the documentation of informed consent and pre- and
posttest counseling. We trained chart abstractors at each site
and reabstracted a random sample of 10% of charts to ensure
quality and consistency of abstractions across sites.
We considered the rationale for testing to be documented if
patients had an ICD-9 risk factor defined as above (including
alcohol use); if the provider documented a risk factor or
another reason for the test, such as clinical presentation
suggestive of HIV infection (including opportunistic infection,
hepatitis B, hepatitis C, or sexually transmitted diseases); or if
the patient requested testing. At the time when testing was
done in our study, guidelines for screening recommended risk-
based testing; as noted, these recommendations have now
changed.
To determine predictors of HIV testing in the at-risk cohort,
and predictors of HIV infection in the tested cohort, we
conducted single predictor analyses and forward-stepwise
logistic regression models that included all the variables that
were statistically significant in the single predictor analysis at
a significance level of P<.05. We used forward-stepwise logistic
regression because collinearity among variables precluded us
from starting with the entire set of predictors, as is required in
backward selection.
RESULTS
Analysis of At-Risk Cohort
Between October 1, 1998, and September 30, 1999, 13,991
unique patients were seen at the 4 VA medical centers that fit
our broadest definition of risk behaviors, which included
substance abuse (including alcohol), hepatitis, or sexually
transmitted diseases (Table 1). Of these patients, only 5,076
(36%) were HIV-tested within the VA during a 5-year period
from October 1, 1995, to September 30, 2000; testing ranged
from 32% to 40% by site (P<.01) (Table 2). When we used a
more restrictive definition of risk behaviors, the total number
of patients who met the definition decreased and the propor-
tion that had been tested increased modestly (Table 1). Even
with the most restrictive definition of at-risk, over half of
patients had not been tested within the VA. Among all at-risk
316 Owens et al.: HIV Testing of At Risk Patients JGIMpatients, HIV testing was more likely among younger age
groups, in patients who were African American, in patients
who had hepatitis or sexually transmitted diseases, or in those
who used cocaine or opiates (Table 3).
Of the 5,076 at-risk patients who were HIV-tested during a
5-year period, 339 (6%) were HIV-infected, ranging from 1% to
19% by site (Table 2). HIV infection was more likely among
patients 30–39 [adjusted OR 12.8 (95% confidence interval, CI:
1.72–95.40)], 40–49 [adjusted OR 10.8 (1.48–79.21)], and 50–
59 years of age [8.8 (1.20–64.93)], respectively, relative to those
>=70 years of age, among African Americans compared to
whites [adjusted OR 2.5 (1.87–3.24)], and among patients with
hepatitis B virus infection [adjusted OR 2.7 (1.82–3.92)]. In
this cohort of HIV-infected patients, in which all patients had
an identifiable risk factor, patients with hepatitis C virus
infection were not more likely than other patients to have HIV
infection.
Analysis of Tested Cohort
There were 4,810 unique patients who received an HIV test at
the 4 VA medical centers during the period between October 1,
1998, and September 30, 1999. Of these, 4,791 (99.6%)
patients could be matched to data from the National Patient
Care Database. We excluded 512 of these patients because
they were either nonveterans (485) or had inconsistent values
for gender (27). We used information from the database to
evaluate the characteristics of the remaining 4,279 patients,
and to gain further clinical detail, we reviewed the charts of a
random sample of 1,100 of these patients drawn equally from
each of the 4 medical centers.
The 4,279 tested patients were predominantly male (94%)
and between the ages of 40 and 59 years (62%). The overall HIV
Table 2. Demographic characteristics and HIV testing results
among at-risk cohort
Site 1
n=4,239
Site 2
n=3,016
Site 3
n=3,227
Site 4
n=3,192
Multi-
site*
n=317
Gender (%)
Male 97 98 97 98 97
Mean
age
(range)
51
(23–92)
51
(21–91)
49
(20–87)
50
(22–94)
48
(27–76)
Race/ethnicity (%)
White 52 41 55 30 50
African
American
14 22 13 33 36
Hispanic 8 4 6 13 7
Other 2 1 2 1 2
Unknown 25 31 25 24 6
Tested for
HIV (%)
40 34 36 32 63
HIV-
positive
(%)
†
15 6 1 9 4
Percentages may not total 100 due to rounding. HIV testing was
conducted from October 1, 1995, to September 30, 2000.
*Multisite refers to patients seen at more than 1 facility.
†Percentage based on number of HIV tests done.
Table 1. Proportion of at-risk patients tested for HIV
At-risk definition Number
at risk
Number
tested
% tested
Alcohol use, substance use,*
hepatitis,
† sexually
transmitted diseases
13,991 5,076 36
Substance use,* hepatitis,
†
sexually transmitted diseases
9,703 4,085 42
Cocaine use, opiate use,
amphetamine use, hepatitis B,
hepatitis C, sexually
transmitted diseases
7,540 3,387 45
Cocaine use, opiate use,
amphetamine use
4,658 2,258 48
*Substance use includes amphetamine use, barbiturate use, cannabis
use, cocaine use, opioid use, hallucinogen use, other drug use, and
unspecified and drug psychosis.
†Includes all viral hepatitis.
Table 3. Predictors of HIV testing among at-risk cohort
Risk factor Adjusted odds ratio 95% confidence interval
Age group (years) (relative to >=70-year-olds)
20–29 4.7* 3.37–6.67
30–39 4.7* 3.75–5.93
40–49 4.2* 3.42–5.19
50–59 3.6* 2.89–4.39
60–69 2.1* 1.69–2.69
Race/ethnicity (relative to white)
African American 1.2* 1.10–1.34
Hispanic 1.2
† 1.02–1.34
Asian 1.1 0.73–1.56
American Indian 1.4 0.83–2.26
Hepatitis (relative to none)
Hepatitis C 2.4* 2.16–2.67
Hepatitis B 1.8* 1.36–2.47
Hepatitis B and C 2.5* 1.90–3.18
Cocaine use 1.6* 1.45–1.76
Opiate use 1.6* 1.42–1.77
Sexually
transmitted
diseases
1.6* 1.31–1.92
Gender, site, alcohol use, and amphetamine use were significant in the
single predictor model but not significant in the stepwise logistic
regression analysis.
*P<.01.
†P<.05.
Table 4. Medical record review of tested patients: HIV test results
and process of care
Site 1 %
n=275
Site 2 %
n=275
Site 3 %
n=275
Site 4 %
n=275
Total %
n=1,100
Testing
rationale
documented
93 95 95 78 90
HIV test
positive*
13 6 2 08
Documentation
of prior
HIV test
35 39 23 22 30
Documentation
of informed
consent*
45 100 99.6 76 80
Documentation
of pretest
counseling*
14 10 87 57 42
Documentation
of posttest
counseling*
8 5 82 45 35
*P<0.01 for comparison between sites.
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1% to 18% by site (P<.01). HIV infection was more likely among
males compared to females [adjusted OR 7.2 (2.23–23.12)] and
African Americans compared to whites [adjusted OR 1.9 (1.4–
2.64)], and varied by site. HIV infection was less likely among
the ages 50–59 [adjusted OR 0.6 (0.41–0.83)] and patients
>=60 years old [adjusted OR 0.21 (0.13–0.35)] compared to 40–
49-year-olds, and among patients who used alcohol [adjusted
OR 0.4 (0.32–0.61)] compared to those who did not (patients
may have had other drug use) or those who used ampheta-
mines [adjusted OR 0.4 (0.15–0.83)] compared to those who
did not. These comparisons were based only on tested
patients, most of whom had risk factors, and thus reflect the
relative importance of risk factors in this group; they do not
indicate, for example, that amphetamine use would not be a
risk factor if assessed in a group with no other risk factors.
Our review of 1,100 medical records provided further detail
about the reasons for and process of testing. The rationale for
testing was documented in 90% of the patients, ranging from
78% to 95% by site. In the remaining patients, the reason for
testing was unclear. The prevalence of HIV infection among the
tested patients included in the chart review was similar to the
overall group of tested patients, with 8% of patients testing
positive (ranging from 1% to 20% by site, P<.01, Table 4).
Documentation of informed consent and pre- and posttest
counseling varied among sites (Table 4). HIV infection was
more likely among patients aged 30 to 49, African Americans,
men who have sex with men, and patients with a history of an
opportunistic infection, and varied by site (Table 5).
DISCUSSION
Our study aimed to assess the degree to which the veteran
population at risk was tested for HIV and whether testing was
based on identifiable risk behaviors among patients who were
tested. Our reviews of testing were performed in 4 relatively
large VA Health Care Systems that care for substantial
numbers of patients with HIV. Although these sites are not
likely to be representative of all VA centers, we have no reason
to believe that testing or screening would be more extensive at
other VA centers than in the ones included in our study.
The most important finding of our study is that only about
one-third to one-half of patients we identified as being at risk
for HIV, based on ICD-9 diagnoses of substance abuse,
hepatitis, or sexually transmitted diseases, had been tested
for HIV within a 5-year period in the VA. This finding was
consistent in the 4 sites we studied. Even when we used more
restrictive definitions of risk factors, slightly less than one-half
of at-risk patients had been tested within the VA. Because the
finding was consistent across our 4 study sites, and because
we have no reason to believe that testing rates would be higher
at smaller VA centers with less-active HIV programs, we believe
that rates of testing of at-risk patients are likely to be too low in
many VA centers. Our finding of low testing rates is of concern
because early identification of HIV infection enables patients to
access life-prolonging therapy at the earliest appropriate time.
Our result is also consistent with studies from non-VA settings
that indicate that patients with HIV are often identified late in
the course of disease.
12–14 For example, Klein and colleagues
13
found that 43% of patients diagnosed in a large health
m a i n t e n a n c eo r g a n i z a t i o nh a dC D 4c o u n t so fl e s st h a n
200 cells/μL. They also found that risk factors were present
before diagnosis in about 25% of patients; our focus was
whether testing occurred when risk factors were known.
We evaluated testing of at-risk patients during the period
from 1995 to 2000, which raises the question of whether
testing practices have changed since that time. Two recent
analyses suggest strongly that they have not. An analysis of a
cohort of 3,760 HIVantiretroviral naïve patients presenting for
HIV care in the VA found that 55% presented late in the course
of disease, with CD4 counts less than 200 cells/mm
3, and 40%
of the patients had used VA services before, for a median
duration of 3.7 years.
22 These findings suggest that a large
proportion of patients were both in care and were not identified
until late in the course of disease. Furthermore, only about
11% of the HIV-infected patients had clinical symptoms or
findings suggestive of HIV infection prior to diagnosis, which
highlights the importance of testing patients based on risk
behaviors. In addition, an analysis of a national sample of at-
risk patients seen in primary care in the VA during 2004 to
2005 found lower rates of testing than in our study (Gifford
and Asch, unpublished).
We had no way to determine whether patients had been
tested in non-VA facilities or whether patients had been offered
testing and refused. However, unlike the military, there are few
if any disincentives for testing within the VA, and our
experience is that it is rare for patients to be tested elsewhere
and refuse testing at the VA.
We found that among patients who were tested, the
rationale for testing was clear and based on risk behaviors or
patient request for approximately 90% of patients. Site 4 had a
modestly lower rate of documentation of the rationale for
testing, but a higher prevalence of positive tests than other
sites, which suggests that testing in this site did identify
patients at risk. We do not know why documentation rates
were lower in site 4. Overall, testing was most often performed
Table 5. Predictors of HIV infection among tested patients from
medical record review
Risk factor Adjusted odds ratio 95% confidence interval
Age group (years) (relative to 40–49-year-olds)
20–29 0.1 0.02–1.43
30–39 1.4 0.70–2.93
50–59 0.4* 0.20–0.81
>=60 0.1
† 0.03–0.37
Race/ethnicity (relative to white)
African American 2.8
† 1.40–5.46
Hispanic 1.7 0.65–4.39
Other 2.5 0.53–12.01
Insurance
‡
Yes 2.4
† 1.30–4.52
Site (relative to site 1)
Site 2 2.0 0.46–8.23
Site 3 3.6 0.98–13.5
Site 4 12.9
† 3.71–45.17
Men who have sex with men
Yes 15.4
† 7.03–33.72
Prior HIV test done
Yes 0.2
† 0.08–0.45
Opportunistic infection
Yes 4.4
† 1.80–10.81
*P<.05.
†P<.01.
‡Patient had additional insurance coverage at the time of HIV testing
(Medicare, Medicaid, other public coverage, or private coverage).
318 Owens et al.: HIV Testing of At Risk Patients JGIMbecause of documentation of substance abuse, with patient
request and infection with hepatitis C as other important
reasons for testing. Because some clinicians may not docu-
ment risk behaviors, or because patients may not volunteer
risk behaviors, the rate of appropriate testing may be even
higher than we estimated. Consistent with non-VA popula-
tions, race (African American), age (30 to 49), risk behaviors
(men who have sex with men), and a history of opportunistic
infections were strong predictors of HIV infection (Table 5).
23–26
Our central finding that only about one-third to one-half of
patients at risk had been tested raises the question of whether
there are barriers to HIV testing. Current VA regulations
require informed consent for testing and pre- and posttest
counseling; documentation of consent and counseling was
variable. The regulations for pre- and posttest counseling
specify required elements of counseling and have been inter-
preted at many VA health care systems as requiring face-to-
face counseling by specially trained personnel. In this respect,
testing for HIV is nearly unique among medical conditions,
with much more cumbersome requirements for diagnosis than
diseases, such as hepatitis C virus infection, which do not
require this process. The new CDC guidelines released in
September 2006 recommend dropping separate informed
consent for HIV testing.
15 In related research, we have found
that the time required for informed consent and counseling are
significant barriers to testing,
27 as have others.
28 We also note,
however, that the quality-of-care literature finds that failure to
perform indicated tests and interventions is common across
many diseases in many health-care delivery systems,
29 so
other factors may be important.
We cannot determine which barriers are responsible for the
low testing rates, but we believe that methods for pre- and
posttest counseling should be reexamined. Furthermore, the
availability of rapid HIV tests that may eliminate the need for a
second visit should also be considered as an approach to HIV
testing. Procedures developed almost 20 years ago may now
present an important impediment to testing. The CDC has
revised its screening guidelines and recommends that separate
informed consent not be required for testing.
In conclusion, we examined practice patterns for HIV testing
in a large integrated health-care system with a notable record
in improving quality of care
16 and a specific focus on improving
quality of care for patients with HIV. The VA may, therefore, be
better positioned to address the identification of HIV infection
than many health-care systems. Nonetheless, although the
vast majority of patients who were tested for HIV were tested
for a well-documented reason, a substantial proportion of at-
risk patients had not been tested. In these patients, a critical
opportunity to provide early therapy and risk-reduction
counseling for HIV-infected patients may have been missed.
This finding suggests that substantially more ambitious
programs for testing will be needed if more at-risk patients
are to be identified early in the course of HIV infection.
3,
9 The
dramatic advances in therapy for HIV warrant robust new
approaches to identify patients early in the course of HIV
disease so that they may receive the full benefit of life-
prolonging therapy and counseling.
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